Our exclusive iSORT^TM (Isolation of Optimal Reverse Immunology Generated TCR) platform is able to isolate TCRs against unique selected tumor-associated intracellular and extracellular antigens and neoantigens in the context of an HLA molecule, allowing us to focus on specific cancers and patient populations based on their genetic makeups. Using this technology, we are able to isolate TCR candidates capable of targeting antigens presented by both class I and class II HLA molecules.

iSORT^TM

iSolation of Optimal Reverse Immunology-generated TCR

• This technology allows T-Cure to isolate novel TCRs against shared antigens
• The isolated TCRs can be HLA Class I and/or Class II restricted
• There is no need for affinity enhancement